Profitability
This table compares Carmell and GBS’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Carmell | N/A | -217.50% | -50.22% |
| GBS | N/A | -85.64% | -54.42% |
Volatility and Risk
Carmell has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, GBS has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.
Earnings and Valuation
This table compares Carmell and GBS”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Carmell | $32,839.00 | 343.76 | -$15.44 million | ($0.46) | -1.17 |
| GBS | N/A | N/A | -$8.31 million | ($0.56) | -1.51 |
GBS has lower revenue, but higher earnings than Carmell. GBS is trading at a lower price-to-earnings ratio than Carmell, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
24.2% of Carmell shares are held by institutional investors. Comparatively, 2.8% of GBS shares are held by institutional investors. 29.0% of Carmell shares are held by insiders. Comparatively, 0.3% of GBS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Carmell beats GBS on 6 of the 9 factors compared between the two stocks.
About Carmell
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.
About GBS
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Receive News & Ratings for Carmell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carmell and related companies with MarketBeat.com's FREE daily email newsletter.
